Brief of PhRMA as Amicus Curiae in Support of Petitioner
PhRMA represents the country’s leading innovative pharmaceutical and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Those efforts produce the cutting-edge medicines, treatments, and vaccines that save, prolong, and improve the quality of the lives of countless individuals around the world every day. Over the past decade, PhRMA’s members have secured FDA approval of more than 300 new medicines. Such results are not obtained cheaply. In 2014 alone, PhRMA members invested roughly $51 billion in development of new medicines.
PhRMA seeks to advance public policies that foster innovation and encourage its members’ investments. To those ends, PhRMA seeks to remove barriers that may arise in the nation’s patent and other systems for protecting the intellectual property of its members—including as amicus curiae before this Court.